SPOTLIGHT -
While twice as many people have open-angle glaucoma than angle-closure glaucoma worldwide, the latter is a more blinding disease, reported Erik L. Greve, MD, PhD.
SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease
(EyePod) From idea to impact: Navigating ophthalmic innovation
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
EyePod: Modifier Gene Therapy: What is it?
Patients with dry eye suffer from worse sleep quality
Ophthalmic industry veteran Erin Schallhorn Powers joins Holland Foundation for Sight Restoration Board of Directors